DNA topoisomerase II-α as a proliferation marker in human gliomas: Correlation with PCNA expression and patient survival

Clinical Neuropathology

Volumn 27, Issue 2, 2008, Pages 83-90

  Zhao, H ^a   Yu, H ^a   Liu, Y ^a   Wang, Y ^a   Cai, W ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

DNA topoisomerase II ; Immunohistochemistry; PCNA glioma; Topo II

Indexed keywords

CARMUSTINE; CYCLINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE 2 ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD;

EID: 41149171919     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/npp27083     Document Type: Article

References (30)

1. Akimitsu N, Kamura K, Tone S, Sakaguchi A, Kikuchi A, Hamamoto H et al. Induction of apoptosis by depletion of DNA topoisomerase IIα in mammalian cells. Biochem Biophys Res Commun. 2003; 307: 301-307.
2. Berger JM, Gamblin SJ, Harrison SC, Wang JC. Structure and mechanism of DNA topoisomerase II. Nature. 1996; 379: 225-232.
3. Braun AH, Stark K, Dirsch O, Hilger RA, Seeber S, Vanhoefer U. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan. Anticancer Drugs. 2005; 16: 1099-1108.
4. Bredel C, Lassmann S, Pollack IF, Knoth R, Hamilton RL, Volk B et al. DNA topoisomerase IIα and Her-2/neu gene dosages in pediatric malignant gliomas. Int J Oncol. 2005; 26: 1187-1192.
5. Bredel M, Gatterbauer B, Birner P, Haberler C, Strobel T, Budka H et al. Expression of DNA topoisomerase IIα in oligodendroglioma. Anticancer Res. 2002a; 22: 1301-1304.
6. Bredel M, Piribauer M, Marosi C, Birner P, Gatterbauer B, Fischer I et al. High expression of DNA topoisomerase IIα and Ki-67 antigen is associated with prolonged survival in glioblastoma patients. Eur J Cancer. 2002b; 38: 1343-1347.
7. Bredel M, Pollack IF, Hamilton RL, Birner P, Hainfellner JA, Zentner J. DNA topoisomerase IIα predicts progression-free and overall survival in pediatric malignant non-brainstem gliomas. Int J Cancer. 2002c; 99: 817-820.
8. Franceschi E, Cavallo G, Scopece L, Paioli A, Pession A, Magrini E et al. Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Br J Cancer. 2004; 91: 1038-1044.
9. Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol. 1996; 27: 149-155.
10. Gray MD, Mann M, Nitiss JL, Hendershot LM. Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIα protein levels and decreasing sensitivity to topoisomerase-targeted drugs. Mol Pharmacol. 2005; 68: 1699-1707.
11. Ho DM, Hsu CY, Ting LT, Chiang H. MIB-1 and DNA topoisomerase IIα could be helpful for predicting long-term survival of patients with glioblastoma. Am J Clin Pathol. 2003; 119: 715-722.
12. Joshi AA, Wu Z, Reed RF, Suttle DP. Nuclear factor-Y binding to the topoisomerase IIα promoter is inhibited by both the p53 tumor suppressor and anticancer drugs. Mol Pharmacol. 2003; 63: 359-367.
13. Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P. Culprit and victim - DNA topoisomerase II. Lancet Oncol. 2002; 3: 235-243.
14. Kiya K, Uozumi T, Ogasawara H, Sugiyama K, Hotta T, Mikami T et al. Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. Cancer Chemother Pharmacol. 1992; 29: 339-342.
15. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002; 61: 215-225, discussion 226-229.
16. Korkolopoulou P, Patsouris E, Konstantinidou AE, Christodoulou P, Thomas-Tsagli E, Kouzelis K et al. Mitosin and DNA topoisomerase IIα: two novel proliferation markers in the prognostication of diffuse astrocytoma patient survival. Appl Immunohistochem Mol Morphol. 2001; 9: 207-214.
17. Koul D, Takada Y, Shen R, Aggarwal BB, Yung WK. PTEN enhances TNF-induced apoptosis through modulation of nuclear factor κB signaling pathway in human glioma cells. Biochem Biophys Res Commun. 2006; 350: 463-471.
18. Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIβ. Clin Cancer Res. 2005; 11: 8467-8475.
19. Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro-Tess JD, Gandola L et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol. 2002; 20: 4209-4216.
20. Matsumoto Y, Kunishio K, Nagao S. Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line. J Neurooncol. 1999; 45: 37-46.
21. Niimi A, Suka N, Harata M, Kikuchi A, Mizuno S. Co-localization of chicken DNA topoisomerase IIα, but not β, with sites of DNA replication and possible involvement of a C-terminal region of α through its binding to PCNA. Chromosoma. 2001; 110: 102-114.
22. Oda M, Arakawa Y, Kano H, Kawabata Y, Katsuki T, Shirahata M et al. Quantitative analysis of topoisomerase IIα to rapidly evaluate cell proliferation in brain tumors. Biochem Biophys Res Commun. 2005; 331: 971-976.
23. Preusser M, Wolfsberger S, Czech T, Slave I, Budka H, Hainfellner JA. Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Am J Clin Pathol. 2005; 124: 543-549.
24. Stein ME, Kuten A, Drumea K, Goldsher D, Tzuk-Shina Z. Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure: a clinical study conducted at the Northern Israel Oncology Center. J Surg Oncol. 1999; 77: 167-170.
25. Taki T, Ohnishi T, Arita N, Hiraga S, Hayakawa T. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance. J Neurooncol. 1998; 36: 41-53.
26. Tews DS, Nissen A, Kulgen C, Gaumann AK. Drug resistance- associated factors in primary and secondary glioblastomas and their precursor tumors. J Neurooncol. 2000; 50: 227-237.
27. Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, Symons M et al. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via rac1 and nuclear factor-αB and correlate with poor patient outcome. Cancer Res. 2006; 66: 9535-9542.
28. Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H. Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol. 1999; 125: 481-486.
29. Yoshida K, Yamaguchi T, Shinagawa H, Taira N, Nakayama KI, Miki Y. Protein kinase C Δ activates topoisomerase IIα to induce apoptotic cell death in response to DNA damage. Mol Cell Biol. 2006; 26: 3414-3431.
30. Zhou Z, Guan H, Kleinerman ES. E1A specifically enhances sensitivity to topoisomerase IIα targeting anticancer drug by up-regulating the promoter activity. Mol Cancer Res. 2005; 3: 271-275.